Most Recent
Three generic drug manufacturers cannot claim damages for an injunction barring the release of cheaper versions of Effexor-XR, even if the injunction was later overturned, pharmaceutical giant Wyeth told a judge on day two of a six-week trial over its blockbuster antidepressant.
Pharmaceutical giant Wyeth's has launched an "ambush" at the beginning of a trial after a nine-year long battle against several generic drug makers, alleging infringement of a second patent for its blockbuster Effexor-XR, a judge heard Monday.
A decade-long courtroom battle over a patent for Effexor-XR that delayed the release of cheap versions of the anti-depressant is at the centre of a trial starting Monday in Sydney pitting four generic drug makers against pharmaceutical giant Wyeth.
GlaxoSmithKline and Novartis have made another admission in a case brought by the ACCC alleging the drug giants made misleading claims in marketing their Voltaren Osteo Gel and Voltaren Emulgel pain relief products.
Pharmaceutical companies AstraZeneca and Generic Health have laid down their swords in a long-running patent dispute over AstraZeneca's cholesterol drug Crestor, two-and-a-half years after the High Court of Australia found the patent obvious and invalid.
Drug giants GlaxoSmithKline and Novartis have conceded part of the ACCC's case that packaging on their Voltaren Osteo Gel breached the Australian Consumer Law, but said the label was changed almost a year ago.
The ACCC will have another go at its case against electronics giant LG next May, according to an order Thursday, and its appeal gives the full Federal Court a chance to clarify whether companies must inform consumers with faulty products of their rights under the Australian Consumer Law.